Effects of Lutein Supplementation on Macular Pigment Optical Density and Visual Acuity in Patients with Age-Related Macular Degeneration

被引:119
作者
Weigert, Guenther [2 ]
Kaya, Semira [1 ]
Pemp, Berthold [1 ,2 ]
Sacu, Stefan [2 ]
Lasta, Michael [1 ]
Werkmeister, Rene Marcel [3 ]
Dragostinoff, Nikolaus [3 ]
Simader, Christian [2 ]
Garhofer, Gerhard [1 ]
Schmidt-Erfurth, Ursula [2 ]
Schmetterer, Leopold [1 ,3 ]
机构
[1] Med Univ Vienna, Dept Clin Pharmacol, A-1090 Vienna, Austria
[2] Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria
[3] Med Univ Vienna, Ctr Med Phys & Biomed Engn, A-1090 Vienna, Austria
关键词
EYE DISEASE; VITAMIN-C; MACULOPATHY; CAROTENOIDS; ZEAXANTHIN; EPIDEMIOLOGY; POPULATION; ANCILLARY; PROGRESS; TRIAL;
D O I
10.1167/iovs.11-7522
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE. There is evidence from several large-scale clinical trials that reduced intake of lutein, a major component of the macular pigment, is a risk factor for the development of AMD. In the present study (LISA; Lutein Intervention Study Austria) it was hypothesized that lutein supplementation increases macular pigment optical density (MPOD). In addition, an investigation was conducted into whether lutein supplementation improves visual acuity (VA) and macular function (mean differential light threshold; MDLT), as assessed with microperimetry. METHODS. One hundred twenty-six patients with AMD (AREDS [Age-related Eye Disease Study] stages 2, 3, and 4) were included in this randomized (2: 1), placebo-controlled, double-masked parallel group study. Lutein or placebo was administered for 6 months. MPOD was measured with a custom-built reflectometer. VA was assessed with ETDRS (Early Treatment Diabetic Retinopathy Study) charts, and MDLT was assessed with a microperimeter. RESULTS. Lutein significantly increased MPOD by 27.9% +/- 2.9% (P = 0.001 versus placebo). No significant effect of lutein supplementation on MDLT or VA was seen, although a tendency toward an increase was seen for both parameters (MDLT, P = 0.096 versus placebo; VA, P = 0.070 versus placebo). A significant correlation was found, however, between the increase in MPOD after 6 months and the increase in MDLT after 6 months (r = 0.25, P = 0.027), as well as between the increase in MPOD after 6 months and the increase in VA after 6 months (r = 0.27, P = 0.013). CONCLUSIONS. The present study demonstrates that lutein supplementation increases MPOD, as assessed with an objective method. The correlation between the change in MPOD and the change in VA and MDLT indicates that patients who show a pronounced increase in MPOD also benefit in terms of visual function. (ClinicalTrials.gov number, NCT00879671.) (Invest Ophthalmol Vis Sci. 2011; 52: 8174-8178) DOI:10.1167/iovs.11-7522
引用
收藏
页码:8174 / 8178
页数:5
相关论文
共 37 条
[11]   Molecular pathology of age-related macular degeneration [J].
Ding, Xiaoyan ;
Patel, Mrinali ;
Chan, Chi-Chao .
PROGRESS IN RETINAL AND EYE RESEARCH, 2009, 28 (01) :1-18
[12]   Influence of short-term antioxidant supplementation on macular function in age-related maculopathy - A pilot study including electrophysiologic assessment [J].
Falsini, B ;
Piccardi, M ;
Iarossi, G ;
Fadda, A ;
Merendino, E ;
Valentini, P .
OPHTHALMOLOGY, 2003, 110 (01) :51-60
[13]   Noninvasive detection of macular pigments in the human eye [J].
Gellermann, W ;
Bernstein, PS .
JOURNAL OF BIOMEDICAL OPTICS, 2004, 9 (01) :75-85
[14]   Assessment of the validity of in vivo methods of measuring human macular pigment optical density [J].
Hammond, BR ;
Wooten, BR ;
Smollon, B .
OPTOMETRY AND VISION SCIENCE, 2005, 82 (05) :387-404
[15]  
Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
[16]   Medical progress: Age-related macular degeneration [J].
Jager, Rama D. ;
Mieler, William F. ;
Miller, Joan W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24) :2606-2617
[17]   Macular pigment density in age-related maculopathy [J].
Jahn, C ;
Wüstemeyer, H ;
Brinkmann, C ;
Trautmann, S ;
Mössner, A ;
Wolf, S .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2005, 243 (03) :222-227
[18]   A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss - AREDS Report No. 8 [J].
Kassoff, A ;
Kassoff, J ;
Buehler, J ;
Eglow, M ;
Kaufman, F ;
Mehu, M ;
Kieval, S ;
Mairs, M ;
Graig, B ;
Quattrocchi, A ;
Jones, D ;
Locatelli, J ;
Ruby, A ;
Capone, A ;
Garretson, B ;
Hassan, T ;
Trese, MT ;
Williams, GA ;
Regan, V ;
Manatrey, P ;
Streasick, P ;
Szydlowski, L ;
McIver, F ;
Bridges, C ;
Stanley, C ;
Cumming, K ;
Lewis, B ;
Zajechowski, M ;
Margherio, RR ;
Cox, MS ;
Camille, J ;
Falk, R ;
Siedlak, P ;
Neubert, C ;
Klein, ML ;
Stout, JT ;
O'Malley, A ;
Lauer, AK ;
Robertson, JE ;
Wilson, DJ ;
Beardsley, C ;
Anderson, H ;
Wallace, P ;
Smith, G ;
Howard, S ;
Dreyer, RF ;
Ma, C ;
Chenoweth, RG ;
Zilis, JD ;
Johnson, M .
ARCHIVES OF OPHTHALMOLOGY, 2001, 119 (10) :1417-1436
[19]   The epidemiology of age-related macular degeneration [J].
Klein, R ;
Peto, T ;
Bird, A ;
Vannewkirk, MR .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2004, 137 (03) :486-495
[20]   Overview of progress in the epidemiology of age-related macular degeneration [J].
Klein, Ronald .
OPHTHALMIC EPIDEMIOLOGY, 2007, 14 (04) :184-187